These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 30577721)

  • 1. Eptacog beta: a novel recombinant human factor VIIa for the treatment of hemophilia A and B with inhibitors.
    Biron-Andreani C; Schved JF
    Expert Rev Hematol; 2019 Jan; 12(1):21-28. PubMed ID: 30577721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eptacog beta, a novel recombinant factor VIIa, for the treatment of hemophilia.
    Watson N; Al-Samkari H
    Drugs Today (Barc); 2022 Mar; 58(3):105-116. PubMed ID: 35274630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and dose-dependency of eptacog beta (activated) in a dose escalation study of non-bleeding congenital haemophilia A or B patients, with or without inhibitors.
    Ducore J; Lawrence JB; Simpson M; Boggio L; Bellon A; Burggraaf J; Stevens J; Moerland M; Frieling J; Reijers J; Wang M
    Haemophilia; 2017 Nov; 23(6):844-851. PubMed ID: 28984010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant factor VIIa (eptacog alfa): a review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders.
    Croom KF; McCormack PL
    BioDrugs; 2008; 22(2):121-36. PubMed ID: 18345709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eptacog Beta for Bleeding Treatment and Prevention in Congenital Hemophilia A and B With Inhibitors: A Review of Clinical Data and Implications for Clinical Practice.
    Ciolek AM; Arnall J; Moore DC; Palkimas S; Der-Nigoghossian J; Dane K
    Ann Pharmacother; 2022 Jul; 56(7):831-838. PubMed ID: 34595941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety evaluation of eptacog beta (coagulation factor VIIa [recombinant]-jncw) for the treatment of hemophilia A and B with inhibitors.
    Pipe SW; Dunn AL; Young G
    Expert Rev Hematol; 2023; 16(10):715-729. PubMed ID: 37602448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PERSEPT 1: a phase 3 trial of activated eptacog beta for on-demand treatment of haemophilia inhibitor-related bleeding.
    Wang M; Lawrence JB; Quon DV; Ducore J; Simpson ML; Boggio LN; Mitchell IS; Yuan G; Alexander WA; Schved JF
    Haemophilia; 2017 Nov; 23(6):832-843. PubMed ID: 28776894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors.
    Chai-Adisaksopha C; Nevitt SJ; Simpson ML; Janbain M; Konkle BA
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011441. PubMed ID: 28944952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant factor VIIa (Eptacog Alfa): a review of its use in congenital or acquired haemophilia and other congenital bleeding disorders.
    Siddiqui MA; Scott LJ
    Drugs; 2005; 65(8):1161-77. PubMed ID: 15907148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors.
    Matino D; Makris M; Dwan K; D'Amico R; Iorio A
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD004449. PubMed ID: 26677005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eptacog beta for the management of patients with haemophilia A and B with inhibitors: A European perspective.
    Miesbach W; Carcao M; Mahlangu J; Dargaud Y; Jimenez-Yuste V; Hermans C
    Haemophilia; 2024 Mar; 30(2):257-266. PubMed ID: 38317441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylaxis in congenital hemophilia with inhibitors: the role of recombinant activated factor VII.
    Franchini M; Manzato F; Salvagno GL; Montagnana M; Zaffanello M; Lippi G
    Semin Thromb Hemost; 2009 Nov; 35(8):814-9. PubMed ID: 20169518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of recombinant factor VIIa in hereditary bleeding disorders.
    Poon MC
    Curr Opin Hematol; 2001 Sep; 8(5):312-8. PubMed ID: 11604567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eptacog alfa activated: a recombinant product to treat rare congenital bleeding disorders.
    Di Minno G
    Blood Rev; 2015 Jun; 29 Suppl 1():S26-33. PubMed ID: 26073366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa.
    Lindley CM; Sawyer WT; Macik BG; Lusher J; Harrison JF; Baird-Cox K; Birch K; Glazer S; Roberts HR
    Clin Pharmacol Ther; 1994 Jun; 55(6):638-48. PubMed ID: 8004880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploratory in vitro evaluation of thrombin generation of eptacog beta (recombinant human fviia) and emicizumab in congenital haemophilia A plasma.
    Grandoni J; Duretz V; Bonzo D; Evans S; Plantier JL
    Haemophilia; 2021 Mar; 27(2):321-328. PubMed ID: 33550714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency.
    Scharrer I
    Haemophilia; 1999 Jul; 5(4):253-9. PubMed ID: 10469179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elective orthopaedic surgery for haemophilia patients with inhibitors: single centre experience of 40 procedures and review of the literature.
    Caviglia H; Candela M; Galatro G; Neme D; Moretti N; Bianco RP
    Haemophilia; 2011 Nov; 17(6):910-9. PubMed ID: 21342367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches.
    Meeks SL; Batsuli G
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):657-662. PubMed ID: 27913543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
    Hedner U
    Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.